Our study provides the foundation for both as data suggest that an assessment of melanoma MMP-23 expression by routine immunohistochemistry may prove useful, much like using immunohistochemistry to determine the estrogen/progesterone receptor status in breast cancer [56]. This evidence concerns the gene MMP23B and breast carcinoma.